Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) EBITDA (2016 - 2025)

Celldex Therapeutics has reported EBITDA over the past 16 years, most recently at -$81.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$81.5 million for Q4 2025, down 66.01% from a year ago — trailing twelve months through Dec 2025 was -$258.4 million (down 63.72% YoY), and the annual figure for FY2025 was -$258.4 million, down 63.72%.
  • EBITDA for Q4 2025 was -$81.5 million at Celldex Therapeutics, down from -$66.6 million in the prior quarter.
  • Over the last five years, EBITDA for CLDX hit a ceiling of -$13.4 million in Q2 2021 and a floor of -$81.5 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$35.1 million (2024), compared with a mean of -$37.0 million.
  • Biggest five-year swings in EBITDA: tumbled 173.29% in 2022 and later increased 16.37% in 2023.
  • Celldex Therapeutics' EBITDA stood at -$20.8 million in 2021, then fell by 20.73% to -$25.1 million in 2022, then tumbled by 67.76% to -$42.1 million in 2023, then decreased by 16.46% to -$49.1 million in 2024, then crashed by 66.01% to -$81.5 million in 2025.
  • The last three reported values for EBITDA were -$81.5 million (Q4 2025), -$66.6 million (Q3 2025), and -$56.8 million (Q2 2025) per Business Quant data.